你可能會喜歡
And to think ~25 years ago Pharma leadership teams (ours included) were debating if drugs will sell for ‘obesity’, as ostentatiously put, it is a lifestyle disease.
$LLY Q3 tirzepatide (Mounjaro/Zepbound) sales: $10.1 billion. $MRK Q3 Keytruda sales $8.1 billion. The passing of the torch...
That is so authentic! You keep fighting Stan the Man. We will keep rooting for you. @stanwawrinka
PASSION - A strong liking, desire, or devotion to an activity. When I started playing tennis at 8 years old, it was just a game. Then it became my passion. My dream was to one day became a professional tennis player. I know that as an athlete, people like to think they know…
Repost far and wide! Thanks for the narrative @simonmaechling
This “study” looks serious. It has an abstract, authors, even affiliations. But read it carefully - it’s pure satire. And it brilliantly exposes one of the biggest flaws in bad science: confusing correlation with causation. “Over 90% of autistic children consumed breast milk or…
This “study” looks serious. It has an abstract, authors, even affiliations. But read it carefully - it’s pure satire. And it brilliantly exposes one of the biggest flaws in bad science: confusing correlation with causation. “Over 90% of autistic children consumed breast milk or…
In April, biotech was the most hated sector of all time. I looked back today and found these two pieces that bucked the trend. Credit @david_wainer and @adamfeuerstein.
Here is my advice to pregnant women Talk to your doctor about the risks and benefits for you and your baby from any medicine Do not take advice from politicians
" Greatness on The Farm 🌲" Stanford Men’s Tennis IG
King is holding court y’all.
Yep. This👇🏼
USA is strong because of the people, not the government. We are a nation of individuals who either got thrown out or chose to come here. A nation founded by immigrants. Freedom of speech. Of religion. To not be oppressed by government. Celebrate our freedom.
#ICYMI: Our CEO, @r_devraj, joined Sam Kessel on the @NucleateHQ podcast to talk target validation, PFMs, and the mission driving Rectify’s work in #PSC and beyond. 🎧 Tune in: bit.ly/4dYMuqQ
🎙️Building Biotech: From the Bench to the Boardroom Raj Devraj (CEO @RectifyPharma, Venture Partner @AtlasVC) shares hard-won lessons on capital efficiency, target validation & startup leadership. A must-listen for biotech founders. 👇 signal.nucleate.xyz/building-biote…
At #EASLCongress 2025 we’re presenting data that demonstrates the potential for a B4/BSEP PFM to address the core pathology of multiple liver & biliary diseases, incl. #PrimarySclerosingCholangitis. Read more: bit.ly/4m8O2lP
We’re attending the 62nd @ERAkidney Congress June 4–7! We’ll present new transitional data from our cardio-renal-metabolic program addressing critical unmet needs in kidney health. More on our presentation: bit.ly/4kvrMRM #ERA25
Thanks for the opportunity @Xtalks to discuss our lead program for #PSC and our #PFM platform that allows us to discover and develop oral, small molecule drugs to rectify membrane protein dysfunction.
Thanks for the opportunity @LongwoodLeaders to converse with a distinguished panel of execs who are balancing and derisking novel science, building novel platforms and bringing differentiated products to serve patients. @LongwoodFund @RectifyPharma
Insightful conversation on #drugdiscovery sciences with biotech CEOs Dee Datta Switch Therapeutics, Brent Vaughan, JJ Kang Appia Bio, Dominique Verhelle NextRNA Therapeutics, @r_devraj @RectifyPharma #longwoodhealthcareleaders #JPM25
Investors in Padlock Therapeutics sue Bristol Myers Squibb $BMY over ‘milestone’ payments The dark side of so-called biobucks deals, featuring @michael_gilman statnews.com/2024/12/12/pad…
statnews.com
Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments
Investors in Padlock Therapeutics have accused Bristol Myers Squibb of reneging on payments of up to $450 million negotiated as part of a 2016 acquisition agreement.
I could not agree more with @JackScannell13
Furthermore, the productivity loss from small decrements in test validity (e.g., by adapting the test to reduce cycle time or to increase throughput) can swamp large gains in brute-force efficiency. Quality beats quantity. 6/8
Furthermore, the productivity loss from small decrements in test validity (e.g., by adapting the test to reduce cycle time or to increase throughput) can swamp large gains in brute-force efficiency. Quality beats quantity. 6/8
United States 趨勢
- 1. Vandy 6,146 posts
- 2. Carnell Tate 1,129 posts
- 3. Vanderbilt 5,541 posts
- 4. French Laundry 3,107 posts
- 5. Donaldson N/A
- 6. Christmas 127K posts
- 7. Clemson 7,985 posts
- 8. #HookEm 2,512 posts
- 9. Julian Sayin 2,054 posts
- 10. Dalot 18.8K posts
- 11. Jeremiah Smith 1,054 posts
- 12. Arch Manning 2,081 posts
- 13. Amad 21.4K posts
- 14. Jim Knowles N/A
- 15. ESPN 79.1K posts
- 16. Buckeyes 2,980 posts
- 17. Disney 89.7K posts
- 18. Colin Simmons N/A
- 19. #GoBucks 1,840 posts
- 20. Casemiro 21K posts
你可能會喜歡
-
Jeb Keiper
@JebKeiper -
Rosana Kapeller
@KapellerRosana -
Nello Mainolfi
@NelloMainolfi -
Alex Harding
@AlexHarding7 -
Jo Viney (she/her)
@76viney -
Art Krieg
@ArtKrieg -
Michael Gladstone
@MikeNGladstone -
David Schenkein
@schenkein -
Carol Suh
@carolysuh -
Ron Renaud
@biotech1969 -
George Vlasuk
@GVlasuk -
Vipin Suri
@VipinSuri4 -
Rick Lundberg
@RickLundberg
Something went wrong.
Something went wrong.